S
Spica Therapeutics
Biotech innovator transforming macrophage biology into breakthrough therapies for oncology and fibroinflammatory diseases
About Spica Therapeutics
Spica Therapeutics is a pioneering biotech company focused on transforming macrophage biology into breakthrough therapies. The company operates in the healthcare sector, specifically targeting oncology and fibroinflammatory diseases. Utilizing a proprietary platform, Spica Therapeutics employs functional macrophage fingerprinting technology to identify and target pathogenic macrophage subsets. This approach aims to improve patient outcomes by modulating macrophages. The company is advancing two lead programs, leveraging the Bioqube venture creation model to develop a robust pipeline of therapies. Headquartered in Belgium with operations in Denmark, Spica Therapeutics is built on a foundation of groundbreaking research published in highly ranked journals. The business model revolves around developing and commercializing therapies that address unmet medical needs, thereby generating revenue through partnerships and product sales.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Aug 2025 | $1.1M | — | VLAIO- Team Bedrijfstrajecten Crossroads France-Wallonie-Vlaanderen | ↗ |
| SEEDOther financing | Jun 2025 | $11M | $44M | PMV · Qbic Fund · Bioqube Ventures | ↗ |
Growth signals
Latest recorded traffic for Spica Therapeutics is 30 monthly website visits, down 98.2% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Spica Therapeutics in the Antwerp ecosystem
The Spica Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
PMV
Bioqube Ventures
Qbic Fund
VLAIO- Team Bedrijfstrajecten Crossroads France-Wallonie-Vlaanderen
Other known investors1 additional known investor
Flanders Institute for Biotechnology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Spica Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Spica Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









